Fostemsavir

DRUG4 trials

Sponsors

ViiV Healthcare, PENTA Foundation, Centre hospitalier de l'Université de Montréal (CHUM)

Conditions

Cardiovascular Risk FactorHIV InfectionsHIV Infections With Multi Drug Resistant VirusHuman Immunodeficiency Virus (HIV)

Phase 1

Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance

Active, not recruitingNCT04648280

PENTA FoundationHIV Infections With Multi Drug Resistant Virus

Start: 2022-06-30End: 2028-12-01Target: 60Updated: 2026-03-05

Phase 2

Reducing Systemic Inflammation in People on Antiretroviral Therapy

RecruitingNCT07030920

Centre hospitalier de l'Université de Montréal (CHUM)Cardiovascular Risk Factor, Human Immunodeficiency Virus (HIV)

Start: 2025-09-30End: 2029-01-31Target: 150Updated: 2025-11-19

Phase 3

A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment

RecruitingNCT07393659

ViiV HealthcareHIV Infections

Start: 2026-07-21End: 2032-09-14Target: 181Updated: 2026-08-14

Unknown Phase

Fostemsavir Compassionate Use Named Patient Program for the Treatment of Human Immunodeficiency Virus 1 (HIV-1)

ViiV HealthcareHIV Infections

Updated: 2025-05-13

Related Papers

SHIELD study: a multicenter, open-label, single-arm trial to evaluate the safety, pharmacokinetics and antiviral activity of fostemsavir in combination with optimized background therapy (OBT) in children and adolescents with HIV who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class antiretroviral (ARV) resistance

BMC Infectious Diseases2026-02-24